10 Days After AR1001 Technology Export Agreement

"Remaining $50 Million Upfront Payment to Be Made in June"

Aribio announced on May 26 that it has received 10 million dollars (approximately 15.1 billion won) out of the 60 million dollars (about 90.6 billion won) upfront payment as part of its global exclusive sales agreement for AR1001 with Chinese pharmaceutical company Fuxing Pharmaceutical.


Aribio Receives $10 Million Upfront Payment from China’s Fuxing Pharmaceutical Under Contract View original image

The total value of this contract is approximately 4.7 billion dollars (about 7.1 trillion won). Aribio explained that foreign currency funds were actually received just about 10 days after the contract announcement.


The company stated that, considering it usually takes several months to remit overseas technology fees due to the approval procedures of the State Administration of Foreign Exchange (SAFE) in China, the execution was relatively fast.


According to the company, Fuxing Pharmaceutical is also in the process of arranging payment procedures for the remaining 50 million dollars (about 75.5 billion won) of the upfront payment within June.


AR1001 is an oral Alzheimer's disease treatment candidate. A global Phase 3 clinical trial, named 'POLARIS-AD', is currently underway. The trial, targeting approximately 1,500 patients across 13 countries, is in its final stages.



Aribio explained that about 95% of all patients are participating in the extension study and that long-term dosing data is also being accumulated.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing